News

Cyclo Therapeutics Announces Launch of New Website

- Company dedicated to developing life-changing medicines through science and innovation for patients and families living with challenging diseases- Pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence site...

Cyclo Therapeutics Announces Inclusion in the Russell 2000® Index

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from...

Trappsol® Cyclo™ is not currently approved for any indication.

Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.